By Angela Onwuzoo
The Federal Government has undertaken a comprehensive review and validation of the National Plan for Vaccine Research & Development and Manufacturing in Nigeria.
The move is to expedite local vaccine manufacturing and halt importation.
The National plan, a first of its kind in Africa, was initially developed in 2021 and delineates the roles of key stakeholders in Nigeria’s vaccine landscape.
The Minister of State for Health and Social Welfare, Dr Tunji Alausa who disclosed this during the review and validation meeting organised by the National Institute for Pharmaceutical Research and Development in Abuja, weekend, said the efforts of the Federal Government over the years to commence local vaccine production are already yielding the expected results.
Represented by Dr. David Atuwo, the minister noted that the review and validation meeting was timely which provided critical stakeholders and policy-makers the opportunity to address critical healthcare issues, as well as enhance entry of the pharmaceutical sector into the larger African market.
The review and validation of the Draft Roadmap, the Minister stressed, will fast-track the achievement of the vaccine policy objectives of the federal government.
“With this initiative, I am confident that the Government prioritization as regards local vaccine production will begin to yield the desired result within the shortest possible time, and the reliance on importation of this important public health tool will be drastically reduced.
“The Federal Ministry of Health and Social Welfare will continue to provide the necessary oversight and work with NIPRD, partners and stakeholders at the various levels to ensure that the desired results of sustainable vaccine R&D and local production in Nigeria are achieved,” the minister said.
Speaking on the Federal Government’s level of preparation to kick-start local vaccine manufacturing, the minister said “Despite the various challenges militating against local production of vaccines, I want to state that appreciable progress has been achieved in these past few years.
“Nigeria has recently attained Maturity Level Three (ML3) for regulatory oversight and this includes the area of vaccines.
“With this and other ongoing reforms in the health sector, vaccines produced as a result of this process will not only satisfy national needs but will also be available for international procurement.
“Whilst the government is taking steps to provide the needed infrastructure requisite for the implementation of local vaccines’ production, it is commendable that NIPRD, in line with its mandate, continues to set the pace for responsive innovation in this area.”
On the importance of the review and validation meeting, Alausa stated: “This high-level meeting is intended to bring together relevant stakeholders to synthesize ideas and solutions for a robust and contextual base plan to achieve sustainable local manufacturing of vaccines in Nigeria.
“This approach will provide a strong foundation that is underpinned by empirical evidence. The adoption of this bottom-up strategy in developing this plan ensures that innovative ideas embedded in this framework are designed to stimulate local vaccines R&D and vaccine production in Nigeria.”
The Director General of NIPRD, Dr. Obi Adigwe, in his remarks explained that the meeting was the first step to unlocking the health value chain plan which will not only save lives but also address critical socio-economic indices such as job creation, capacity building, revenue generation and technology transfer.
Adigwe, however, stressed that Africa no longer cherished what he described as tokenistic interventions such as fill-finish products.
“Africa no longer has an interest in tokenistic interventions such as fill-finish products, but has become interested in building dependable, equitable, and veracious partnerships that will enable the Continent to undertake full R&D for the production of vaccines,” he noted.
Copyright PUNCH
All rights reserved. This material, and other digital content on this website, may not be reproduced, published, broadcast, rewritten, or redistributed in whole or in part without prior express written permission from PUNCH.
Contact: [email protected]
